Showing 1 of 1 recruiting trials for “hyperprolinemia-type-2”
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →